At its May 30 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) endorsed the approval of several cancer therapies. Cejemly The drug review panel recommended granting marketing authorization for Cejemly (sugemalimab, SFL Pharmaceuticals Deutschland GmbH), intended for the first-line treatment of metastatic non–small cell lung cancer (NSCLC) …
